On June 16, “2023 China Pharmaceutical CDMO Enterprise Ranking” was released at the 8th China Pharmaceutical R&D-Innovation Summit, and Jiuzhou Pharmaceutical was awarded “2023 China Pharmaceutical CDMO Enterprise Top 20”; on June 27, the 2022 China Pharmaceutical Industry Top 100 series list organized by Minnetwork was released, and Jiuzhou Pharmaceutical was awarded “China CXO Enterprise Top 20 List”. “On June 27, the 2022 China Top 100 Pharmaceutical Industry List organized by Minnetwork was released, and Jiuzhou Pharmaceutical won the “Top 20 China CXO Enterprises”, which is the fifth consecutive year that Jiuzhou Pharmaceutical has won this award. The continuous inclusion in the important list is the industry authority's high recognition and affirmation of the comprehensive strength of Jiuzhou Pharmaceutical's innovative drug custom R&D and production, as well as the incentive and praise for the sustainable development of the enterprise in the future.

Over the years, Jiuzhou Pharmaceutical has continued to increase the layout of the CDMO business segment, giving full play to its advantages in quality, EHS system, operation management, technological innovation, etc., and expanding its customer pipeline and product pipeline in depth, achieving high quality growth in commercialization and new projects, and enriching its project pipeline day by day.

With years of new drug R&D and technology accumulation, the company has mastered many cutting-edge green pharmaceutical technologies with independent intellectual property rights. At present, we have built a number of technology platforms, including chiral catalytic technology, continuous technology, fluorine chemistry technology, enzyme catalytic technology, photocatalytic technology, electrochemical technology, crystallization technology, peptide technology, formulation research platform, etc. We have been able to solve the technological challenges faced by our customers through a large number of project practices and successful technological transformations, and to provide industry-specific technological solutions for our customers' projects. Caring for life, maintaining health. Jiuzhou Pharmaceutical will, as always, adhere to the development strategy of technological innovation-driven, internationalized layout, focus on building a CDMO one-stop service brand, and is committed to becoming a life and health enterprise with global drug innovation solutions, continuously empowering customers to accelerate the process of launching innovative drugs to the market for the benefit of patients around the world.
 

On June 16, “2023 China Pharmaceutical CDMO Enterprise Ranking” was released at the 8th China Pharmaceutical R&D-Innovation Summit, and Jiuzhou Pharmaceutical was awarded “2023 China Pharmaceutical CDMO Enterprise Top 20”; on June 27, the 2022 China Pharmaceutical Industry Top 100 series list organized by Minnetwork was released, and Jiuzhou Pharmaceutical was awarded “China CXO Enterprise Top 20 List”. “On June 27, the 2022 China Top 100 Pharmaceutical Industry List organized by Minnetwork was released, and Jiuzhou Pharmaceutical won the “Top 20 China CXO Enterprises”, which is the fifth consecutive year that Jiuzhou Pharmaceutical has won this award. The continuous inclusion in the important list is the industry authority's high recognition and affirmation of the comprehensive strength of Jiuzhou Pharmaceutical's innovative drug custom R&D and production, as well as the incentive and praise for the sustainable development of the enterprise in the future.

Over the years, Jiuzhou Pharmaceutical has continued to increase the layout of the CDMO business segment, giving full play to its advantages in quality, EHS system, operation management, technological innovation, etc., and expanding its customer pipeline and product pipeline in depth, achieving high quality growth in commercialization and new projects, and enriching its project pipeline day by day.

With years of new drug R&D and technology accumulation, the company has mastered many cutting-edge green pharmaceutical technologies with independent intellectual property rights. At present, we have built a number of technology platforms, including chiral catalytic technology, continuous technology, fluorine chemistry technology, enzyme catalytic technology, photocatalytic technology, electrochemical technology, crystallization technology, peptide technology, formulation research platform, etc. We have been able to solve the technological challenges faced by our customers through a large number of project practices and successful technological transformations, and to provide industry-specific technological solutions for our customers' projects. Caring for life, maintaining health. Jiuzhou Pharmaceutical will, as always, adhere to the development strategy of technological innovation-driven, internationalized layout, focus on building a CDMO one-stop service brand, and is committed to becoming a life and health enterprise with global drug innovation solutions, continuously empowering customers to accelerate the process of launching innovative drugs to the market for the benefit of patients around the world.
 

On June 16, “2023 China Pharmaceutical CDMO Enterprise Ranking” was released at the 8th China Pharmaceutical R&D-Innovation Summit, and Jiuzhou Pharmaceutical was awarded “2023 China Pharmaceutical CDMO Enterprise Top 20”; on June 27, the 2022 China Pharmaceutical Industry Top 100 series list organized by Minnetwork was released, and Jiuzhou Pharmaceutical was awarded “China CXO Enterprise Top 20 List”. “On June 27, the 2022 China Top 100 Pharmaceutical Industry List organized by Minnetwork was released, and Jiuzhou Pharmaceutical won the “Top 20 China CXO Enterprises”, which is the fifth consecutive year that Jiuzhou Pharmaceutical has won this award. The continuous inclusion in the important list is the industry authority's high recognition and affirmation of the comprehensive strength of Jiuzhou Pharmaceutical's innovative drug custom R&D and production, as well as the incentive and praise for the sustainable development of the enterprise in the future.

Over the years, Jiuzhou Pharmaceutical has continued to increase the layout of the CDMO business segment, giving full play to its advantages in quality, EHS system, operation management, technological innovation, etc., and expanding its customer pipeline and product pipeline in depth, achieving high quality growth in commercialization and new projects, and enriching its project pipeline day by day.

With years of new drug R&D and technology accumulation, the company has mastered many cutting-edge green pharmaceutical technologies with independent intellectual property rights. At present, we have built a number of technology platforms, including chiral catalytic technology, continuous technology, fluorine chemistry technology, enzyme catalytic technology, photocatalytic technology, electrochemical technology, crystallization technology, peptide technology, formulation research platform, etc. We have been able to solve the technological challenges faced by our customers through a large number of project practices and successful technological transformations, and to provide industry-specific technological solutions for our customers' projects. Caring for life, maintaining health. Jiuzhou Pharmaceutical will, as always, adhere to the development strategy of technological innovation-driven, internationalized layout, focus on building a CDMO one-stop service brand, and is committed to becoming a life and health enterprise with global drug innovation solutions, continuously empowering customers to accelerate the process of launching innovative drugs to the market for the benefit of patients around the world.